Pfizer reports positive phase 3 data in atopic dermatitis

Pfizer has announced top-line results from a second Phase 3 study evaluating the efficacy and safety of its oral JAK1 inhibitor, abrocitinib, in patients aged 12 or over with moderate to severe atopic dermatitis.

The study, called JADE MONO-2, used 391 subjects and was designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over the course of 12 weeks.

read more

Geen nieuws missen?
Volg de duizenden farma professionals die via e-mail lezen

Uw inschrijving is gelukt.